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ABSTRACT
A 47 year old female was found to have a 1.8 x 4.9 
cm right adrenal nodule and 2.8 x 4.3 cm left adrenal 
nodule with calcification on CT during abdominal 
pain evaluation. Extensive workup was done that was 
negative for pheochromocytoma and Conn syndrome. 
Her work up showed hypercortisolism with laboratory 
studies revealing high urine free cortisol, unsuppressed 
cortisol on 1mg & 8mg overnight dexamethasone 
suppression testing (ODST), high 11pm salivary 
cortisol X2 along with elevated random cortisol and 
undetectable ACTH. She had normal DHEA-S, plasma 
metanephrine, androsteindione, renin and aldosterone 
levels. 
Since her adenomas were > 4cms bilaterally, adrenal 
surgery was indicated due to increased risk of adrenal 
carcinoma1. Adrenal venous sampling (AVS) done with 
dexamethasone 2 mg PO Q6hours X 1 day, for nodule 
functional assessment, showed elevated right and left 
adrenal cortisol and epinephrine levels compared to 
Inferior vena cava levels. Adrenal vein epinephrine levels 
stepup >100pg/mL indicated successful catheterization. 
Bilateral adrenal vein to venocaval cortisol ratio >4 was 
consistent with autonomous cortisol secretion, and left 
to right adrenal cortisol ratio < 2 suggested bilateral 
Cushing’s based on literature from Mayo Clinic2. 
Initial step was right adrenalectomy but was deferred 
for her carotid artery surgery. She also had multiple co-
morbidities including uncontrolled hypertension, poor 
functional status requiring walker and cane, chronic 
cellulitis, glucose intolerance, and hypokalemia. Medical 
management of hypercortisolism prior to surgery was 
needed. Mifepristone was initiated after her carotid 
surgery. She had > 50lbs weight loss, improved blood 
pressure, complete healing of chronic lower extremity 
cellulitis, and she could ambulate independently by 
4 months of Mifepristone initiation. Her potassium, 
blood pressure and liver functions tests were closely 
monitored. Her right adrenal adenoma resection on 
pathology had multiple adrenocortical nodules without 
adrenal carcinoma and measured 6.5 x 5.0 x 1.7cm.
Learning objectives: Mifepristone, FDA approved for 
inoperable Cushing, facilitated pre-surgery optimization 
by mitigating hypercortisolism. Mifepristone could 
potentially be utilized as a bridge when surgery needs 
to be deferred.
CASE & CLINICAL COURSE
47 year old female with past medical history significant for hypertension, hyperlipidemia, glucose intolerance, carotid artery disease, peripheral 
vascular disease, coronary artery bypass grafting, and chronic leg cellulitis presented with abdominal pain. Initial work up included CT scan of 
the abdomen which showed right adrenal nodule 1.8 x 4.9 cm and left adrenal nodule 2.8 x 4.3 cm. She had workup for pheochromocytoma and 
Conn syndrome which were negative but was positive for Cushing syndrome. See Table 1.
Surgery team evaluated the patient and recommended right adrenalectomy, which 
was the larger of the two adenomas. However to assess if one of the adrenal 
nodule was producing excessive cortisol adrenal venous sampling was performed 
using Dexamethasone 2mg oral every 6 hrs for 24 hrs preceding the procedure. 
See Table 2.
Difference in adrenal gland epinephrine levels compared to peripheral levels 
was > 100 pg/ml suggesting successful localization of the catheter. Adrenal 
vein to peripheral vein cortisol ratio > 4 was consistent with bilateral cortisol 
secretion. Ratio of left to right adrenal cortisol levels < 2 again was consistent 
with bilateral cortisol hypersecretion. It was determined patient should undergo 
right adrenalectomy as it was larger in size compared to the left adrenal adenoma. 
See Figure 1.
The procedure was deferred as patient needed carotid artery surgery. Patient 
needed medical management for hypercortisolism during the interim. She also 
had several co-morbidities including uncontrolled hypertension on Metoprolol 
and Lisinopril, hypokalemia on Potassium supplements, chronic leg cellulitis on 
antiobiotics for 10 months, glucose intolerance, and poor functional status requiring 
walker and cane. Ketoconazole was contraindicated for interactions with plavix and 
atorvastatin which could not discontinued due to her vascular disease. Mifepristone 
was initiated at 300mg PO every other day and titrated up to once daily. She had 
65lb(240lbs to 175lb) weight loss, hypertension improved, had complete healing of 
cellulitis, and could ambulate independently by 4 months of starting Mifepristone. 
Her potassium, liver function tests and BP were monitored closely. Patient stopped 
taking Mifepristone 1 week prior to the right adrenalectomy. Perioperatively she 
was placed on hydrocortisone and eventually tapered off. Post surgery, she did not 
require hydrocortisone or Mifepristone. Symptomatically she had increased energy 
levels, nausea had resolved and denied any weakness. 
Pathology showed a right adrenal mass measuring 6.5X5.0X1.7cm larger than on 
the CT scan dimension containing multiple andrenocoritcal nodules without any 
evidence of mitosis, necrosis or vascular invasion and the immunostaining was 
negative for adrenal carcinoma. She continues to be followed in the outpatient 
endocrinology clinic her work up shows suppressed ACTH with high normal cortisol, 
suggestive of persistent Cushing’s despite unilateral surgical adrenal resection. 
See Table 3.
TABLE 1. 
24 hr urine free cortisol (4-50ug/24hrs) 89.2 
1mg ODST Cortisol (<1.8 ug/dL) 15.7
8mg ODST cortisol (<1.8ug/dL) 20.0
11pm salivary cortisol x2 (<100ng/dL) 156 & 151
Random cortisol (3-22 ug/dL) 17.3
Random ACTH (6-50pg/ml) Undetectable 




Site Cortisol (3-22ug/dL) Epinephrine (<84pg/ml)
Left adrenal gland 84.9 433
Right adrenal gland 56.5 1911




This case had unique diagnostic and management dilemmas. Aldosterone in AVS, reportedly used 
in case reports, might have helped in diagnosis, given the subtly low right adrenal cortisol and 
low left adrenal epinephrine levels (likely from phrenic vein dilution) but based on size, bilateral 
adrenal resection was indicated. Simultaneous aldosterone assessment has been used in case 
reports during adrenal venous sampling and this would have provided additional information but 
was not used in our case3. The patient needed medical management for hypercortisolism during 
the interim before adrenalectomy. Mifepristone is a glucocorticoid receptor antagonist that affinity 
18 times greater than that of endogenous cortisol and has been FDA approved for inoperable 
Cushing’s4. The evaluation of response is based on clinical evaluation and not laboratory 
measurements. Side effects include hypokalemia, worsening blood pressure and increase risk for 
adrenal insufficiency4.
Persistent hypercortisolism increases the risk of perioperative morbidity by increasing 
infectious complications and delayed tissue healing5. The options of outpatient management 
of hypercortisolism include ketoconazole, metyrapone and mifepristone. Ketoconazole could 
not be used due to drug interactions with atorvastatin, and metyrapone is not readily available. 
Mifepristone has been FDA approved and studied in the SEISMIC trial with positive clinical reports 
in managing specific signs and symptoms of Cushing’s6. The drug was utilized in this case to 
antagonize the hypercortisolism, which facilitated healing of her chronic cellulitis, optimized her 
functional status, improved her blood pressure and reduced her weight by greater than 50lbs. 
Following her right adrenal resection, her work up showed suppressed ACTH and suggestive of 
persistant cushing. She will be evaluated for continued Cushing’s symptoms and will obtain a 
repeat 11pm salivary cortisol level x 2. She has the left adrenal adenoma intact, measuring >4cm 
which will need resection in the future. Mifepristone could potentially be used as bridge therapy 
when surgery needs to be deferred.
TABLE 3. 
7am Cortisol (4-22ug/dL) 17.5 (post op day #21)
ACTH (6-50 pg/ml) Undetectable (post op day #41)
7am Cortisol (4-22ug/dL) 17.5 (post op day #41)
ACTH (6-50 pg/ml) Undetectable (post op day #41)
 
  
Figure 1. CT	scan	abdomen	showing	right	and	left	adrenal	
adenomas,	respectively.
